- Institut de Recerca Biomèdica de Lleida (IRB-Lleida)
Research institute
![Foto de - Institut de Recerca Biomèdica de Lleida (IRB-Lleida)](/img/noimage.png)
![Foto de Hospital Virgen de la Arrixaca](/img/noimage_org.png)
Hospital Virgen de la Arrixaca
Murcia, EspañaPublications in collaboration with researchers from Hospital Virgen de la Arrixaca (44)
2024
-
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
Neurologia, Vol. 39, Núm. 2, pp. 196-208
-
Vaccine–carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination
Clinical Research in Cardiology, Vol. 113, Núm. 2, pp. 223-234
2023
-
Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 7, pp. 1658-1666
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60
2022
-
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
Frontiers in immunology, Vol. 13, pp. 842354
-
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
Neurologia, Vol. 37, Núm. 8, pp. 615-630
-
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology
Multiple Sclerosis and Related Disorders, Vol. 63
-
Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial
JAMA Network Open, Vol. 5, Núm. 1
2021
-
Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies
Neurodegenerative Disease Management, Vol. 11, Núm. 3, pp. 251-261
-
Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement
Neurologia, Vol. 36, Núm. 1, pp. 50-60
2020
-
Changes in causes of death and influence of therapeutic improvement over time in patients with heart failure and reduced ejection fraction
Revista Espanola de Cardiologia, Vol. 73, Núm. 7, pp. 561-568
-
Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
Neurology and Therapy, Vol. 9, Núm. 1, pp. 173-179
2019
-
Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)
Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479
-
Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)
Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441
2018
-
Review of the novelties from the 2017 ECTRIMS congress, presented at the 10th post-ectrims meeting (I)
Revista de Neurologia, Vol. 67, Núm. 1, pp. 15-27
-
Review of the novelties from the 2017 ectrims congress, presented at the 10th post-ectrims meeting (II)
Revista de Neurologia, Vol. 67, Núm. 2, pp. 50-62
2017
-
La fracción de eyección intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca
Revista Espanola de Cardiologia, Vol. 70, Núm. 5, pp. 338-346
-
Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure
International Journal of Cardiology, Vol. 240, pp. 265-270
-
Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)
Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84